SMARTSET GMV GENTAMICIN BONE CEMENT

K081163 · DePuy Orthopaedics, Inc. · MBB · May 14, 2008 · Orthopedic

Device Facts

• Record ID: K081163
• Device Name: SMARTSET GMV GENTAMICIN BONE CEMENT
• Applicant: DePuy Orthopaedics, Inc.
• Product Code: MBB · Orthopedic
• Decision Date: May 14, 2008
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 888.3027
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

SmartSet GMV Gentamicin Bone Cement is indicated for use in the second stage of a two-stage revision for total joint arthroplasty after the initial infection has been cleared.

Device Story

SmartSet GMV Gentamicin Bone Cement is a self-curing, radiopaque, polymethylmethacrylate (PMMA)-based bone cement containing gentamicin sulfate. It is used by orthopedic surgeons in clinical settings to secure metal or polymeric prostheses to living bone during the second stage of two-stage revision arthroplasty procedures after an initial infection has been resolved. The cement acts as a mechanical fixation agent, providing structural stability between the implant and the bone while delivering the antibiotic locally.

Clinical Evidence

No clinical data provided; substantial equivalence is based on technological and formulation characteristics.

Technological Characteristics

Self-curing, radiopaque, polymethylmethacrylate (PMMA)-based bone cement containing gentamicin sulfate. Class II device (21 CFR 888.3027).

Indications for Use

Indicated for patients undergoing the second stage of a two-stage revision for total joint arthroplasty following the clearance of an initial infection.

Regulatory Classification

Identification

Polymethylmethacrylate (PMMA) bone cement is a device intended to be implanted that is made from methylmethacrylate, polymethylmethacrylate, esters of methacrylic acid, or copolymers containing polymethylmethacrylate and polystyrene. The device is intended for use in arthroplastic procedures of the hip, knee, and other joints for the fixation of polymer or metallic prosthetic implants to living bone.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Polymethylmethacrylate (PMMA) Bone Cement.”

Predicate Devices

• SmartSet GMV Endurance Gentamicin Bone Cement (K041656)
• SmartSet GHV Gentamicin Bone Cement (K033563)

Submission Summary (Full Text)

{0}------------------------------------------------

## 510(k) Summary

MAY 1 4 2008

Date Prepared:

23 April 2008

510(k) Sponsor:

Establishment Registration No:

Contact Person:

Trade Name of Device:

Common Name:

Classification Name:

Equivalent to:

Device Description:

Intended Use:

Technological Characteristics:

Special 510(k) SmartSet GMV Gentamicin Bone Cement April 2008

DePuy Orthopaedics, Inc 700 Orthopaedic Drive Warsaw, Indiana 46581 - 0988

1818910

Suzana Otaño Project Manager, Regulatory Affairs Telephone: [phone] Fax: [phone] Email: [e-mail]

SmartSet GMV Gentamicin Bone Cement

Antibiotic bone cement

Bone cement, antibiotic

(21 CFR 888.3027, Product Code MBB and LOD)

SmartSet GMV Endurance Gentamicin Bone Cement (K041656)

SmartSet GHV Gentamicin Bone Cement (K033563)

SmartSet GMV Gentamicin Bone Cement is a self-curing, radiopaque, polymethylmethacrylate based cement, containing the antibiotic gentamicin sulfate. The bone cement is used for securing a metal or polymeric prosthesis to living bone in arthroplasty procedures.

SmartSet GMV Gentamicin Bone Cement is indicated for use in the second stage of a two-stage revision for total joint arthroplasty after the initial infection has been cleared.

The technological characteristics of the SmartSet GMV Gentamicin Bone Cement are equivalent to the predicate devices.

Page 25 of 112

{1}------------------------------------------------

## Substantial Equivalence:

.

:

:

:

:

The indications, intended use, formulation and finished product specifications of the SmartSet GMV Gentamicin Bone Cement are equivalent to the predicate devices.

.

: :

Page 26 of 112

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized eagle with three stripes extending from its wing, symbolizing service, science, and security. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.

Public Health Service

MAY 1 4 2008

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

DePuy Orthopaedics, Inc. % Ms. Suzana Otano Project Manager, Regulatory Affairs 700 Orthopaedic Drive Warsaw, IN 46581-0988

Re: K081163

Trade/Device Name: SmartSet GMV Gentamicin Bone Ccment Regulation Number: 21 CFR 888.3027 Regulation Name: Polymethylmethacrylate (PMMA) bone cement Regulatory Class: II Product Code: LOD, MBB Dated: April 23, 2008 Received: April 24, 2008

Dear Ms. Otano:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

### Page 2 - Ms. Suzana Otano

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance. please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at [phone]. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at [phone]. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number [phone] or [phone] or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

Mark M. Milliman

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

# Indications for Use Statement

510(k) Number:

## Device Name: SmartSet GMV Gentamicin Bone Cement

Indications For Use:

SmartSet GMV Gentamicin Bone Cement is indicated for use in the second stage of a two-stage revision for total joint arthroplasty after the initial infection has been cleared.

X Prescription Use

AND/OR

Over-the-Counter

(Per 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Neil RP Ogle firman

(Division Sign-Off Division of General, Restorative, and Neurological Devices

Page 1 of 1

510(k) Number K081163

Special 510(k) SmartSet GMV Gentamicin Bone Cement April 2008

Page 24 of 112